Previous 10 | Next 10 |
home / stock / dskyf / dskyf news
Esperion Therapeutics (ESPR) has signed a new licensing agreement granting the exclusive rights to Daiichi Sankyo Company (DSKYF) to commercialize bempedoic acid and the bempedoic acid/ezetimibe combination tablet in additional countries.The deal allows Daiichi Sankyo to commercialize th...
AstraZeneca (AZN) and Daiichi Sankyo (DSKYF) announce that the National Institute for Health and Care Excellence ((NICE)) has recommended Enhertu (trastuzumab deruxtecan) for use within the Cancer Drugs Fund ((CDF)) as an option for treating HER2 positive unresectable or metastatic breas...
Takeda Pharmaceutical (TAK) and Daiichi Sankyo (DSKYF) are planning to initiate two separate COVID-19 vaccine trials in Japan, the country’s Nikkei newspaper reported on Sunday.While Daiichi will start clinical trials for its vaccine candidate next month, Takeda with the invo...
Daiichi Sankyo Co Ltd (DSKYF) Q3 2020 Earnings Conference Call January 29, 2020 1:00 AM ET Company Participants Toshiaki Sai - EVP and CFO Wataru Takasaki - Executive Officer and Head, R&D Division Conference Call Participants Kazuaki Hashiguchi - Daiwa Securities Fumiyoshi Sakai - Credit...
The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with their 2021 Q3 earnings call. For further details see: Daiichi Sankyo Company, Limited 2021 Q3 - Results - Earnings Call Presentation
Daiichi Sankyo (DSKYF): 9M GAAP EPS of ¥38.94.Revenue of ¥738.79B (-2.4% Y/Y)Press Release For further details see: Daiichi Sankyo reports Q3 results
AstraZeneca (AZN) and its collaborating partner, Daiichi Sankyo (DSKYF) have reported new data from two studies evaluating datopotamab deruxtecan (Dato-DXd; DS-1062) and Enhertu (trastuzumab deruxtecan), in lung cancer. Data were presented during the World Conference on Lung Cancer....
AstraZeneca (AZN) and Daiichi Sankyo's (DSKYF) Enhertu (trastuzumab deruxtecan) has been granted conditional approval in the European Union ((EU)) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more pri...
AstraZeneca (AZN) and Daiichi Sankyo's (DSKYF) antibody drug conjugate Enhertu wins approval from the U.S. FDA for treating adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal ((GEJ)) adenocarcinoma who have received a prior trastuzumab-based...
AstraZeneca (AZN) and Daiichi Sankyo ([[DSKYF]] +2.5%) have reported updated results from Phase 2 trial of Enhertu, which continued to demonstrate ‘impressive’ efficacy and durable responses in patients with HER2-positive metastatic breast cancer.Updated data demonstrated t...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Company Name:
DSKYF Stock Symbol:
OTCMKTS Market:
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...